Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
  • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
  • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

• the present invention relates to gastroresistant spheroids coated with a flexible and deformable film, and to multiparticulate tablets comprising said spheroids.
• the present invention further extends to the method of preparing such enteric spheroids and to the multiparticulate tablets comprising these spheroids.
• the present invention concerns, finally, a new use of a mixture of mono-, di- and triglycerides and of polyethylene glycol monoester and diester.
• spheroids are meant spherical units whose size can vary from 0.1 mm to 2 mm, preferably from 0.1 mm to 2 mm.
• the enteric coating allows the core comprising the active principle to remain intact during the residence time in the stomach, of approximately two hours, in a medium whose pH is approximately between 1 and 3. Once inside the small intestine, comprising the duodenum, jejunum and ileum, the enteric coating will dissolve rapidly in a medium whose pH is greater than 4.5 and increases steadily up to a pH of approximately 7.2 in its distal part.
• the prior art includes numerous examples of multi-particulate tablets comprising coated granules.
• the tableting of coated granules is a delicate operation, altering the structure of the coating film by the appearance of fissures or by rupture; it may cause complete or partial loss of the properties of the film.
• Films composed solely of enteric polymers or copolymers such as Eudragit® L30D have very mediocre mechanical properties, such that they are not resistant to tableting.
• One alternative may consist of the addition to the enteric film of other polymers endowed with mechanical properties which render them suitable for tableting.
• another solution consists in diluting the granules with auxiliary substances, whose role is to absorb the physical stresses of tableting (binders) and to allow the breakdown of the tablet (disintegrants) in a liquid medium, i.e., in aqueous solution or in the digestive fluid.
• WO 02/19991 relates to a multiparticulate tablet and gastroresistant micro-granules, said microgranules comprising an enteric coating of a copolymer of methacrylic acid and propylene glycol.
• the proportion of said granules within the tablets is between 35% and 90%, preferably 40% to 70% by weight, relative to the total weight of the tablet, the remainder being a binder.
• the Applicant's International application WO 99/26608 relates to spheroids which comprise one or more active principles and are tabletable directly without the addition of a substantial part of an auxiliary substance.
• These spheroids are composed of a core comprising the active principle, said core being covered with a first layer comprising at least one thermoplastic excipient whose consistency is pasty to semisolid at a temperature of the order of 20° C. and whose melting temperature is between approximately 25° C. and approximately 100° C., the resulting spheroid being itself coated with a flexible and deformable film based on a polymeric material.
• these spheroids Although particularly suited to the preparation of gastroresistant forms, these spheroids exhibit the disadvantage of being composed of a plurality of successive layer of different compositions, entailing a lengthy and constricting preparation process, and of using thermoplastic excipients whose pasty to semisolid consistency at 20° C. makes them not very easy to handle.
• Gélucire® in enteric polymer-based coatings makes it possible to improve, surprisingly, their mechanical properties in such a way that the spheroids coated with this coating composition may subsequently be tableted directly without the addition of more than approximately 5% by weight of auxiliary substances.
• the present invention provides a directly tabletable gastroresistant spheroid, characterized in that it comprises:
• directly tabletable is meant that the spheroids can be tableted in the form of multiparticulate tablets without any need to add more than approximately 5% of auxiliary substances at the time of tableting.
• the core comprises one or more active principles selected from those from the group consisting of gastrointestinal sedatives, antacids, analgesics, antiinflammatories, coronary vasodilators, peripheral and cerebral vasodilators, antiinfection agents, antibiotics, antivirals, antiparasitics, anticancer agents, anxiolytics, neuroleptics, central nervous system stimulants, antidepressants, antihistamines, antidiarrheals, laxatives, nutritional supplements, immunodepressants, hypocholesterolemics, hormones, enzymes, antispasmodics, antianginal agents, medicinal products which influence heart rate, medicinal products used in the treatment of arterial hypertension, antimigraine agents, medicinal products which influence blood clottability, antiepileptics, muscle relaxants, medicinal products used in the treatment of diabetes, medicinal products used in the treatment of thyroid dysfunctions, diuretics, anorexigenic agents, antiasthmatics, expectorants, antitussives,
• active principles in this application are the active principles which are labile in an acid medium, necessitating gastric-acid protection for oral administration; for example, proton pump inhibitors, such as omeprazole, lansoprazole, pantoprazole, pariprazole, leminoprazole and rabeprazole, in their racemic form or in the form of pure enantiomers, themselves in base form or in the form of alkali metal salts.
• proton pump inhibitors such as omeprazole, lansoprazole, pantoprazole, pariprazole, leminoprazole and rabeprazole
• active principles are the active principles which are irritant to the mucosa of the stomach, and whose ulcerogenic effects necessitate delayed administration, such as nonsteroidal anti-inflammatories, diclofenac for example, antibiotics such as erythromycin and its derivatives, and doxycycline.
• delayed administration such as nonsteroidal anti-inflammatories, diclofenac for example, antibiotics such as erythromycin and its derivatives, and doxycycline.
• the active principle or principles are applied by application to the surface of a neutral core of a mixture of sucrose and starch, or of microcrystalline cellulose, or else, according to an alternative method, are dispersed in the mass of the core, by dry, wet or hot granulation, or by extrusion with spheronization.
• the active principle initially in the form of a powder or microcrystals, is used in the form of a solution or suspension in an aqueous or organic solvent for application to neutral substances, and is used generally in the dry state in other cases.
• the cores also comprise a binder.
• the binder is selected from the group consisting in particular of cellulosic polymers, acrylic polymers, povidones, copovidones, polyvinyl alcohols, alginic acid, sodium alginate, starch, pregelatinized starch, sucroses and derivatives thereof, guar gum, polyethylene glycols, and mixtures thereof.
• cellulosic polymers selection will be made advantageously of ethylcellulose, hydroxypropyl-cellulose, and hydroxypropylmethylcellulose, alone or in a mixture.
• acrylic polymers selection is made, advantageously, of ammonio-methacrylate copolymer, the polymers and copolymers of acrylic and methacrylic acid, polyacrylates and polymethacrylates, used alone or in a mixture.
• the binder is present in proportions which can range up to approximately 50% by weight, preferably up to approximately 20% by weight, relative to the weight of the uncoated cores.
• the core optionally comprises a diluent and an antistat.
• the diluent may be selected from the group consisting in particular of cellulosic derivatives and preferentially microcrystalline cellulose, starches on their own, lactose, polyols, preferentially mannitol, and minerals, preferentially dicalcium phosphate.
• the diluent is present in proportions which can range up to approximately 95% by weight, preferably up to approximately 50% by weight, relative to the weight of the uncoated particles.
• Its role is to increase the total mass of particles to be coated, and to provide a population of particles of uniform size.
• the antistat may be selected from the group consisting in particular of colloidal silica, such as that sold under the brand name Aerosil®, preferably precipitated silica, such as that sold under the name Syloid® FP244, micronized or nonmicronized talc, and mixtures thereof.
• the antistat is present in proportions which can range up to approximately 10% by weight, preferably up to approximately 3% by weight, relative to the weight of the uncoated particles, and enhances the fluidization of the substance when a fluidized-air bed is used, especially in the case of powder granulation.
• An optional polymeric layer may be applied between the core and the flexible and deformable polymeric film, in order to isolate the active core from the polymer layer, thereby making it possible to reinforce the gastric-acid protection of the active principle.
• the polymer is selected from the same polymers as those used as binder. It may be identical to or different from that used as binder in the active core.
• the amount of polymer applied is between 1% and 10% by weight gain relative to the mass of active cores employed, preferably between 2% and 5%.
• the core comprising the active principle is subsequently coated with a flexible and deformable film which makes it possible to ensure that the active principle is protected from gastric acid, and which is composed of an enteric polymer and at least one plasticizer.
• the enteric polymer is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate phthalate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylcellulose, shellac or any other enteric polymer, which are used alone, in a mixture, or combined separately.
• the preferred polymer is the methacrylic acid copolymer sold under the brand name Eudragit® L100 or Eudragit® L30D.
• the coating composition is applied by spraying to give a continuous film which covers all of the surface of each particle, irrespective of its surface condition, in an amount sufficient to ensure that the active principle is protected against gastric acid.
• Protection against gastric acid is determined by means of a two-step test which consists in measuring the dissolution profile of the coated form, such that, when the latter is placed in a dissolution medium with a pH of 1.2, the percentage of active principle released after 120 minutes is less than 10% by weight, and then when, after modification of the pH of the medium from a value of 1.2 to a pH with a value of 6.8, the percentage of active principle released after 60 minutes at this pH is at least 80%, expressed by weight.
• the enteric polymer is present in proportions which can range up to approximately 50%, preferably up to approximately 20%, calculated by weight gain relative to the mass of cores to be coated.
• the solvent selected for spraying the enteric polymer may be water, an organic solvent, such as ethanol, isopropanol or acetone, or a mixture of solvents.
• the polymer is in the form of a solution, a suspension or a colloidal dispersion in the solvent or mixture of solvents. It is preferably in the form of a colloidal dispersion in water.
• this polymer may be mixed with a second polymer or copolymer, which may itself be soluble or insoluble; in particular, a neutral copolymer of acrylic and methacrylic esters, sold under the brand name Eudragit® NE30D.
• a second polymer or copolymer which may itself be soluble or insoluble; in particular, a neutral copolymer of acrylic and methacrylic esters, sold under the brand name Eudragit® NE30D.
• a second polymer to the coating composition makes it possible to enhance the mechanical properties of the enteric film resulting from this mixture.
• the second polymer is added in an amount of not more than 100%, calculated by dry weight of polymer relative to the dry weight of the enteric polymer, preferably in a ratio of between 10% and 30%.
• the mixture of saturated and/or unsaturated polyglycosylated glycerides whose fatty acids contain at least 8 carbon atoms is in particular a mixture of mono-, di- and triglycerides and of polyethylene glycol (PEG) monoester and diester, with a molecular weight of between 200 and 1500, and optionally of glycerol and of free PEG.
• PEG polyethylene glycol
• the fatty acids of the mixture of saturated and/or unsaturated polyglycosylated glycerides preferably contain from 8 to 18 carbon atoms (C8-C18).
• C8-C18 denotes mixtures, in significative and variable proportions, of caprylic (C8), capric (C10), lauric (C12), myristic (C14), palmitic (C16), and stearic (C18) acid, when these acids are saturated, and the corresponding unsaturated acids (C8-C18).
• the proportions of these fatty acids may vary depending on the starting-product oils.
• Gélucires® preference is given to Gélucire® 50/13, which thus comprises predominantly palmitostearic acid (C16-C18) and is characterized by a melting point of between 46.0 and 51.0° C. and a hydrophilic/lipophilic balance (HLB) of 13.
• the total proportion of the mixture of saturated and/or unsaturated polyglycosylated glycerides is not more than 40%, preferably between 10% to 30%, expressed by weight relative to the dry weight of polymer.
• the function of the mixture of saturated and/or unsaturated polyglycosylated glycerides is to lower the glass transition temperature of the film and to enhance the mechanical properties of the polymeric coating film; in particular, to render it flexible and deformable.
• the coating film further comprises a plasticizer selected from the group consisting of triethyl citrate, acetyl tributyl citrate, triacetin, tributyl citrate, diethyl phthalate, polyethylene glycols, polysorbates, and mono- and diacetylated glycerides.
• a plasticizer selected from the group consisting of triethyl citrate, acetyl tributyl citrate, triacetin, tributyl citrate, diethyl phthalate, polyethylene glycols, polysorbates, and mono- and diacetylated glycerides.
• the plasticizer is used in a total proportion of not more than 40%, preferably between 10% to 30%, expressed by weight relative to the dry weight of polymer.
• the function of the plasticizer is to lower the glass transition temperature of the film.
• the coating composition optionally further comprises a surfactant, an antistat and/or a lubricant.
• the surfactant is selected from anionic, cationic, nonionic or amphoteric surfactants.
• the antistat is used in order to avoid the problems associated with static electricity. It is in the group consisting of micronized or nonmicronized talc, colloidal silica (Aerosil® 200), treated silica (Aerosil® R972), or precipitated silica (Syloid® FP244), and mixtures thereof.
• the antistat is used in a proportion of not more than approximately 10% by weight, preferably between 0 and 3%, and preferably less than approximately 1% by weight.
• the lubricant is selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, micronized polyoxyethylene glycols, sodium benzoate, and mixtures thereof.
• the spheroids have a diameter of between 0.1 mm and 2 mm, preferably between 0.3 mm and 1 mm.
• the size is determined by conventional techniques; for example, with the aid of a set of calibrated-mesh screens, or by laser diffraction.
• the spheroids according to the invention are advantageously coated with a water-dispersible outer layer.
• This layer ensures the mutual cohesion of the spheroids at the time of tableting and thus ensures the hardness of the tablet, and allows disintegration of the resulting tablet in aqueous medium.
• the water-dispersible outer layer is composed of at least one disintegrant.
• the disintegrant is selected from the group consisting in particular of the crosslinked sodium carboxymethyl-cellulose denoted in the art by the term croscarmellose, crospovidone, sodium carboxymethyl starch, and mixtures thereof.
• It may optionally comprise a binder selected from those used for the assembly step, and water-soluble auxiliary substances such as polyols, in particular mannitol.
• the invention likewise relates to the method of preparing the directly tabletable gastroresistant spheroids.
• the method in accordance with the invention comprises the following steps:
• the steps may be carried out within different apparatus or the same apparatus.
• the core comprising the active principle may be obtained by granulation, by application to neutral substance, or else by extrusion with spheronization.
• a high-energy granulator for granulation, a high-energy granulator, a planetary mixer or a fluidized-air bed are advantageously used.
• said cores are prepared by application to neutral substances according to the following steps:
• the application preparation may, depending on the case in hand, be in the form of a suspension in aqueous or organic media, in the form of solutions, in the form of emulsions, or in the melted state.
• the active principle is incorporated into the application preparation.
• the active principle is applied by dusting to the neutral cores wetted beforehand with the application preparation.
• All of the steps of the method according to the invention may be carried out in a pan-coating turbine, in a perforated turbine or in a fluidized-air bed.
• the cores comprising the active principle are prepared by extrusion with spheronization.
• the active principle is mixed into the mass of excipient.
• the mixture is wetted in order to ensure satisfactory extrusion, and the extrudates thus obtained are calibrated and spheronized.
• the cores thus obtained are subsequently coated by means of a composition
• a composition comprising a film-forming enteric polymer, a plasticizer, and, optionally, a surfactant, an antistat and/or a lubricant.
• the coating composition is sprayed in the form of a solution, a suspension or a colloidal dispersion of this polymer in an aqueous or organic solvent, and then dried.
• the water-dispersible outer layer is applied with one of the above techniques, but isopropyl alcohol is the solvent preferably used.
• all of the steps of preparing the active core and coating are carried out in a fluidized-air bed.
• the fluidized-air bed is equipped with a spraying nozzle whose position and spraying orientation are selectable.
• the spraying mode is referred to as “top spray”, “bottom spray” or “tangential spray”, in accordance with the customary terminology of the skilled worker.
• the selection of the spraying mode makes it possible to master the growth kinetics of the particles and to prevent sticking phenomena, associated with the nature of the active principle, with the binder or coating composition sprayed, and with the various parameters of the method (temperature, air pressure, for example, flow rate of solution).
• the present invention likewise provides multi-particulate tablets comprising the aforedescribed directly tabletable spheroids and comprising not more than approximately 5% by weight in total of an auxiliary substance, such as a lubricant, an antistat and/or a permeabilizing agent.
• an auxiliary substance such as a lubricant, an antistat and/or a permeabilizing agent.
• the lubricant is selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, micronized polyoxyethylene glycols, sodium benzoate, and mixtures thereof.
• the antistat is used in order to avoid problems associated with static electricity. It is in the group consisting of micronized or nonmicronized talc, colloidal silica (Aerosil® 200), treated silica (Aerosil® R972) or precipitated silica (Syloid® FP244), and mixtures thereof.
• the permeabilizing agent is selected from the group consisting in particular of silicas having high affinity for aqueous solvents, such as the precipitated silica better known under the brand name Syloid®, maltodextrins, ⁇ -cyclodextrins, and mixtures thereof.
• the permeabilizing agent makes it possible to create a hydrophilic network which hence contributes to more effective breakdown of the tablet.
• the multiparticulate tablets according to the invention disintegrate in solution in less than 60 minutes and restore independent spheroids, such that the release profile of the tablet and of the spheroids constituting it are virtually equivalent.
• the tablets according to the invention allow the delivery of spheroids without the release profile of the active principle or principles they contain being adversely affected under the effect of tableting.
• the tablets according to the invention may be composed solely of spheroids according to the invention or of a mixture of spheroids comprising one or more active principles and of placebo spheroids: that is, spheroids in accordance with the present invention but without active principle.
• the tablets according to the invention may be subjected to a final coating for protection or coloration.
• the invention likewise relates to the method of preparing multiparticulate tablets comprising the spheroids.
• the method according to the invention comprises the following steps:
• the spheroids can be tableted on an alternating or rotary tableting machine.
• the stresses exerted on the spheroids during the tableting step may vary from 5 kN to 50 kN and preferably between 5 kN and 15 kN.
• the hardness of these tablets is preferably between 1 and 10 kp, more preferably between 1 and 5 kp, measured in accordance with the method of the European Pharmacopeia (2.9.8), 1 kp being equal to 9.8N.
• the hardness of the multiparticulate tablet is preferably adapted so as to give a friability, measured according to the method of the European Pharmacopeia, of less than 2%.
• the breakdown time of the tablets in an aqueous medium at 37° C. is less than 60 minutes.
• the tablets may have a diameter of between 6 mm and 17 mm. Their shape may be round, oval, oblong, with a flat or concave surface, and may have grooves or bars for divisibility.
• the tablets according to the invention preferably have a mass of between 0.1 g and 2 g.
• the dissolution profile of the gastroresistant spheroids is determined under the following conditions:
• the coated granules G 1 obtained from the coating step have the following dissolution profile: TABLE 1 Theophylline released % (w/w) Time G1 pH 1.2 120 min 7 ⁇ pH 6.8 135 min 81 150 min 81 180 min 81
• the spheroids have a dissolution profile which meets the specifications of the gastroresistance test.
• the granules G 1 from example 1 are coated with an outer layer composed of a binder but devoid of disintegrant.
• the granules G 1 are sprayed with an aqueous solution containing either PEG 4000 or a mixture of PEG 4000 and HPMC 603 in a 20/80 ratio, additionally comprising 20% by weight of micronized talc, calculated relative to the total dry weight of polymer.
• Each sub-batch of granules is tableted separately on a Manesty F3 press equipped with a circular, convex punch with a diameter of 10 mm, so as to give a friability value of less than 2% by weight.
• the dispersible outer layer devoid of a disintegrant does not allow the tablet to break down in accordance with the specifications.
• the granules G 1 from example 1 are coated with a water-dispersible layer comprising a disintegrant, Ac-Di-Sol®.
• the Ac-Di-Sol® mixed with mannitol 25 in a 50/50 ratio, is applied to the granules G 1 by dusting in a conventional turbine, using a binder solution comprising polyvinylpyrrolidone (PVP) K29, in 10% solution in isopropyl alcohol.
• PVP polyvinylpyrrolidone
• the granules G1/1 thus prepared have the following dissolution profile: TABLE 2 Theophylline released % (w/w) Time G1/1 pH 1.2 120 min 7 ⁇ pH 6.8 135 min 79 150 min 79 180 min 80 Tableting
• the granules obtained in the preceding step, G1/1 are tableted on a Manesty F3 press equipped with a circular, convex punch with a diameter of 10 mm, to give a unit dose of theophylline of approximately 50 mg.
• the tablets (C1/1) thus obtained have the following characteristics: TABLE 3 G1/1 Weight (mg) 426 Hardness (kP) 2.7 Friability (%) 0.21 Break down (min) 50 Theophylline released % (w/w) pH 1.2 120 min 51 ⁇ pH 6.8 135 min 87 150 min 88 180 min 88
• the water-dispersible layer comprising Ac-Di-Sol® allows the tablet to break down in less than 60 minutes, but the tableting of the granules causes the polymeric film to rupture and the gastric-acid protection to be lost.
• the tablet does not meet the specifications of the gastroresistance test.
• the granules G 1 from example 1 are coated with a water-dispersible layer comprising a disintegrant, Kollidon® CLM.
• the Kollidon® CLM mixed with mannitol 25 in a 50/50 ratio, is applied to the granules G 1 by dusting in a conventional turbine, using a binder solution comprising PVP K29, in 10% solution in isopropyl alcohol.
• the granules thus prepared (G1/2) have the following dissolution profile: TABLE 4 Theophylline released % (w/w) Time G1/2 pH 1.2 120 min 5 ⁇ pH 6.8 135 min 82 150 min 82 180 min 82 Tableting
• the granules obtained in the preceding step are tableted on a Manesty F3 press equipped with a circular, convex punch with a diameter of 10 mm, to give a unit dose of theophylline of approximately 70 mg.
• the tablets (C1/2) thus obtained have the following characteristics: TABLE 5 C1/2 Weight (mg) 409 Hardness (kP) 2.5 Friability (%) 0.51 Break down (min) 32 Theophylline released % (w/w) pH 1.2 120 min 41 ⁇ pH 6.8 135 min 80 150 min 81 180 min 82
• the water-dispersible layer comprising the disintegrant allows the tablet to break down in less than 60 minutes, but the tableting of the granules causes the polymeric film to rupture and the gastric-acid protection to be lost.
• the tablet does not meet the specifications of the gastroresistance test.
• the coated granules G2 thus coated have the following dissolution profile: TABLE 6 Theophylline released % (w/w) Time G2 pH 1.2 120 min 3 ⁇ pH 6.8 135 min 92 150 min 109 180 min 110 Overcoating
• the granules G2 obtained in the preceding step are coated with a water-dispersible layer comprising Kollidon® CLM.
• the Kollidon® CLM mixed with mannitol 25 in a 50/50 ratio, is applied to the granules by dusting in a conventional turbine, using a binder solution comprising PVP K29, in 10% solution in isopropyl alcohol.
• the coated granules obtained in the preceding step (G2/1) are tableted on a Manesty F3 press equipped with a circular, convex punch with a diameter of 12 mm, to give a unit dose of theophylline of approximately 150 mg.
• the tablets (C2/1) thus obtained have the following characteristics: TABLE 7 C2/1 Weight (mg) 400 Hardness (kP) 6.0 Friability (%) Nd Break down (min) 26 Theophylline released % (w/w) pH 1.2 120 min 3 ⁇ pH 6.8 135 min 64 150 min 89 180 min 92
• the spheroids meet the specifications of the gastroresistance test.
• the tablet meets the specifications of the disintegration and gastroresistance test.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=32011398

Family Applications (2)

Family Applications After (1)

Country Status (16)

Cited By (5)

Families Citing this family (7)

Citations (6)

Family Cites Families (12)

• 2002
  • 2002-10-04 FR FR0212333A patent/FR2845289B1/fr not_active Expired - Fee Related
• 2003
  • 2003-10-03 EP EP03775466A patent/EP1549298B1/de not_active Expired - Lifetime
  • 2003-10-03 CN CN2003801037982A patent/CN1713896B/zh not_active Expired - Fee Related
  • 2003-10-03 SI SI200331253T patent/SI1549298T1/sl unknown
  • 2003-10-03 CA CA2501294A patent/CA2501294C/fr not_active Expired - Fee Related
  • 2003-10-03 MX MXPA05003588A patent/MXPA05003588A/es active IP Right Grant
  • 2003-10-03 ES ES03775466T patent/ES2307993T3/es not_active Expired - Lifetime
  • 2003-10-03 AT AT03775466T patent/ATE399001T1/de active
  • 2003-10-03 US US10/530,052 patent/US20060165794A1/en not_active Abandoned
  • 2003-10-03 PT PT03775466T patent/PT1549298E/pt unknown
  • 2003-10-03 DK DK03775466T patent/DK1549298T3/da active
  • 2003-10-03 DE DE60321801T patent/DE60321801D1/de not_active Expired - Lifetime
  • 2003-10-03 WO PCT/FR2003/002909 patent/WO2004030657A1/fr not_active Ceased
  • 2003-10-03 AU AU2003283492A patent/AU2003283492A1/en not_active Abandoned
  • 2003-10-03 JP JP2004540887A patent/JP4660192B2/ja not_active Expired - Fee Related
• 2008
  • 2008-08-25 CY CY20081100901T patent/CY1108285T1/el unknown
• 2010
  • 2010-04-23 US US12/766,176 patent/US9446002B2/en not_active Expired - Fee Related

Patent Citations (6)

Also Published As

Similar Documents

Legal Events